Evidence map›Paper›PMID 22200082›Full record

ArticleJournal of the American Chemical Society2012

Targeted catalytic inactivation of angiotensin converting enzyme by lisinopril-coupled transition-metal chelates.

Jeff C Joyner, Lalintip Hocharoen, J A Cowan

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 57 citations in OpenAlex.

  1. DNA Scission by Non-Histidine Amino-Terminal Cu(II) and Ni(II) Binding-Like Peptides.Chembiochem : a European journal of chemical biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Optochemical Control of Biological Processes in Cells and Animals.Angewandte Chemie (International ed. in English) · 2018
    Review
  9. Article
  10. Article
  11. Catalytic metallodrugs based on the LaR2C peptide target HCV SLIV IRES RNA.Dalton transactions (Cambridge, England : 2003) · 2015
    Article
  12. Article
  13. Inactivation of sortase A mediated by metal ATCUN complexes.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014
    Article
  14. Article
  15. Article
  16. Target-directed catalytic metallodrugs.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2013
    Review
  17. Antimicrobial metallopeptides with broad nuclease and ribonuclease activity.Chemical communications (Cambridge, England) · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jeff C JoynerEvans Laboratory of Chemistry, The Ohio State University, 100 West 18th Avenue, Columbus, Ohio 43210, USA.
Lalintip Hocharoen
J A Cowan
The Ohio State University · US

Funding

CHEMISTRY/BIOLOGY TRAINING GRANTT32GM008512 · NIGMS · OHIO STATE UNIVERSITY · PI PEI, DEHUA · 1996 to 2016
$3.9M
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV InfectionR44AA016712 · NIAAA · METALLOPHARM, LLC · PI COWAN, ADA S · 2011 to 2013
$2.0M
METALLOPEPTIDES AS THERAPEUTIC AGENTSR21HL093446 · NHLBI · OHIO STATE UNIVERSITY · PI COWAN, JAMES A · 2009 to 2010
$408k
Novel Engineered Synthetic Metallodrugs Directed Against HCVR43AA016712 · NIAAA · METALLOPHARM, LLC · PI CHING, SAN · 2007 to 2008
$257k
NHLBI NIH HHS HL093446NHLBI NIH HHS R21 HL093446NIAAA NIH HHS AA016712NIAAA NIH HHS R43 AA016712NIAAA NIH HHS R44 AA016712NIGMS NIH HHS T32 GM008512NIGMS NIH HHS T32 GM08512
6 · The paper itself

Abstract

A series of compounds that target reactive transition-metal chelates to somatic angiotensin converting enzyme (sACE-1) have been synthesized. Half-maximal inhibitory concentrations (IC(50)) and rate constants for both inactivation and cleavage of full-length sACE-1 have been determined and evaluated in terms of metal chelate size, charge, reduction potential, coordination unsaturation, and coreactant selectivity. Ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and tripeptide GGH were linked to the lysine side chain of lisinopril by 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride/N-hydroxysuccinimide coupling. The resulting amide-linked chelate-lisinopril (EDTA-lisinopril, NTA-lisinopril, DOTA-lisinopril, and GGH-lisinopril) conjugates were used to form coordination complexes with iron, cobalt, nickel, and copper, such that lisinopril could mediate localization of the reactive metal chelates to sACE-1. ACE activity was assayed by monitoring cleavage of the fluorogenic substrate Mca-RPPGFSAFK(Dnp)-OH, a derivative of bradykinin, following preincubation with metal chelate-lisinopril compounds. Concentration-dependent inhibition of sACE-1 by metal chelate-lisinopril complexes revealed IC(50) values ranging from 44 to 4500 nM for Ni-NTA-lisinopril and Ni-DOTA-lisinopril, respectively, versus 1.9 nM for lisinopril. Stronger inhibition was correlated with smaller size and lower negative charge of the attached metal chelates. Time-dependent inactivation of sACE-1 by metal chelate-lisinopril complexes revealed a remarkable range of catalytic activities, with second-order rate constants as high as 150,000 M(-1) min(-1) (Cu-GGH-lisinopril), while catalyst-mediated cleavage of sACE-1 typically occurred at much lower rates, indicating that inactivation arose primarily from side chain modification. Optimal inactivation of sACE-1 was observed when the reduction potential for the metal center was poised near 1000 mV, reflecting the difficulty of protein oxidation. This class of metal chelate-lisinopril complexes possesses a range of high-affinity binding to ACE, introduces the advantage of irreversible catalytic turnover, and marks an important step toward the development of multiple-turnover drugs for selective inactivation of sACE-1.

Indexed as

Angiotensin-Converting Enzyme InhibitorsCatalysisChelating AgentsHumansLisinoprilModels, MolecularPeptidyl-Dipeptidase ATransition ElementsAngiotensin-Converting Enzyme InhibitorsChelating AgentsLisinoprilPeptidyl-Dipeptidase ATransition Elements

Identifiers

PMID22200082
PMCPMC3401419
OpenAlexW2044616443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.